DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)
CNY 16.16
(0.56%)
CNY 16.16
(0.56%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.64 Billion CNY | -61.35% |
| 2022 | 4.25 Billion CNY | 1.13% |
| 2021 | 4.2 Billion CNY | 248.23% |
| 2020 | 1.2 Billion CNY | 363.54% |
| 2019 | 260.44 Million CNY | 1114.42% |
| 2018 | 21.44 Million CNY | 0.0% |
| 2017 | - CNY | -100.0% |
| 2016 | 28.8 Million CNY | -64.29% |
| 2015 | 80.64 Million CNY | -16.0% |
| 2014 | 96 Million CNY | 860.0% |
| 2013 | 10 Million CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 1.79 Billion CNY | -10.29% |
| 2024 Q1 | 1.78 Billion CNY | 9.04% |
| 2024 Q2 | 1.99 Billion CNY | 11.74% |
| 2023 Q2 | 4.29 Billion CNY | 1.87% |
| 2023 Q3 | 4.31 Billion CNY | 0.31% |
| 2023 Q4 | 1.64 Billion CNY | -61.9% |
| 2023 FY | 1.64 Billion CNY | -61.35% |
| 2023 Q1 | 4.21 Billion CNY | -0.75% |
| 2022 Q4 | 4.25 Billion CNY | 3.28% |
| 2022 Q3 | 4.11 Billion CNY | 0.53% |
| 2022 Q1 | 4.12 Billion CNY | -1.91% |
| 2022 FY | 4.25 Billion CNY | 1.13% |
| 2022 Q2 | 4.09 Billion CNY | -0.7% |
| 2021 Q4 | 4.2 Billion CNY | 5.71% |
| 2021 FY | 4.2 Billion CNY | 248.23% |
| 2021 Q2 | 3.88 Billion CNY | 7.84% |
| 2021 Q1 | 3.6 Billion CNY | 198.45% |
| 2021 Q3 | 3.97 Billion CNY | 2.35% |
| 2020 Q1 | 13.45 Million CNY | -94.83% |
| 2020 Q2 | - CNY | -100.0% |
| 2020 Q4 | 1.2 Billion CNY | 0.0% |
| 2020 FY | 1.2 Billion CNY | 363.54% |
| 2020 Q3 | - CNY | 0.0% |
| 2019 Q1 | 18.76 Million CNY | -12.5% |
| 2019 FY | 260.44 Million CNY | 1114.42% |
| 2019 Q2 | 851.26 Million CNY | 4436.35% |
| 2019 Q4 | 260.44 Million CNY | -69.6% |
| 2019 Q3 | 856.63 Million CNY | 0.63% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 Q2 | - CNY | 0.0% |
| 2018 Q3 | - CNY | 0.0% |
| 2018 Q4 | 21.44 Million CNY | 0.0% |
| 2018 FY | 21.44 Million CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 Q2 | 14.4 Million CNY | 0.0% |
| 2017 Q3 | - CNY | -100.0% |
| 2017 Q1 | 14.4 Million CNY | -50.0% |
| 2017 FY | - CNY | -100.0% |
| 2016 FY | 28.8 Million CNY | -64.29% |
| 2016 Q4 | 28.8 Million CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2015 FY | 80.64 Million CNY | -16.0% |
| 2015 Q4 | 80.64 Million CNY | 0.0% |
| 2015 Q1 | 88.32 Million CNY | 0.0% |
| 2015 Q2 | 88.32 Million CNY | 0.0% |
| 2014 FY | 96 Million CNY | 860.0% |
| 2013 FY | 10 Million CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |